<DOC>
	<DOCNO>NCT00388076</DOCNO>
	<brief_summary>Pazopanib give TAXOL one part , another part pazopanib give TAXOL PARAPLATIN , third part pazopanib give TAXOL lapatinib ( patient separate part ) . Toxicity monitor enable u find large dose pazopanib daily safely give combination chemotherapy agent TAXOL PARAPLATIN , lapatinib , well side effect likely manifest agent give together whether combination pazopanib chemotherapy , help treat different type cancer . Another objective find much pazopanib , TAXOL , PARAPLATIN lapatinib blood specific time agent give . Collecting blood sample require patient remain vicinity clinic overnight 2 occasion .</brief_summary>
	<brief_title>Pazopanib ( VOTRIENT ) Plus Paclitaxel ( TAXOL ) , Pazopanib Plus Paclitaxel ( TAXOL ) Plus Carboplatin ( PARAPLATIN ) , Pazopanib Plus Paclitaxel ( TAXOL ) Plus Lapatinib ( TYKERB )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis cancer , except cervical cancer Eastern Cooperative Oncology Group performance Status 0 1 Peripheral neuropathy Grade 1 less Adequate bone marrow function ( absolute neutrophil , platelet hemoglobin level per protocol ) Adequate renal function per protocol Urine creatinine ratio per protocol Adequate hepatic function per protocol Coagulation test per protocol Male female least 18 year age A woman eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include woman : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , Is postmenopausal ( total cessation menses least 1 year ) Childbearing potential , negative serum urine pregnancy test screening , agree one following : An intrauterine device ( IUD ) document failure rate le 1 % per year . Vasectomized partner sterile prior patient 's entry sole sexual partner woman . Complete abstinence sexual intercourse 14 day exposure investigation product , throughout clinical trial , least 21 day last dose investigational product . Doublebarrier contraception define condom spermicidal jelly , foam , suppository , film ; OR male condom diaphragm . Predicted life expectancy least 12 week Written inform consent Able swallow retain oral medication . Exclusion criterion : No 3 prior line cytotoxic chemotherapy metastatic disease allow . No major surgery , cytotoxic chemotherapy , investigational agent , radiotherapy within last 28 day subject must recover fully whatever last treatment time enrollment . Women pregnant breast feed eligible enroll . Can poorly control hypertension . Can correct QT ( QTc ) prolongation Can Class III IV heart failure define New York Heart Association functional classification system . Can arterial venous thrombus ( include cerebrovascular accident ) , myocardial infarction , admission unstable angina , cardiac angioplasty , stenting within last 3 month . Can use therapeutic warfarin . Can history bleeding ( hemoptysis , hematuria , GI blood loss , epistaxis , others great Grade 1 accord CTC Criteria ) within six week prior begin therapy clinical indication current active bleeding bleed diathesis . Can history clinical evidence CNS metastases leptomeningeal carcinomatosis , except individual previously treat CNS metastasis , asymptomatic , requirement steroid antiseizure medication 2 month prior begin study treatment . Can serious and/or unstable preexist medical , psychiatric , condition ( include laboratory abnormality ) could interfere patient safety obtain consent . Can history malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could affect absorption , distribution , metabolism excretion pazopanib , paclitaxel , carboplatin . Has unresolved bowel obstruction diarrhea . Has clinically significant gastrointestinal abnormality may increase risk GI bleed include , limited : active peptic ulcer disease , know intraluminal metastatic lesion ( ) suspect bleeding , inflammatory bowel disease include ulcerative colitis , GI condition increase risk perforation , history abdominal fistula , GI perforation , intraabdominal abscess within 28 day prior begin study treatment . Subject must psychological , familial , sociological , geographical condition permit compliance protocol . Subject must take specifically prohibit medication specify protocol study require medication treatment pazopanib . Subject must clinical history , current alcohol illicit drug use , judgment Investigator , would interfere patient 's ability comply dose schedule protocolspecified evaluation . Subject must allergic either TAXOL PARAPLATIN , taxane platinum contain compound . Subject must current diagnosis cervical cancer . Subject must know endobronchial metastasis involvement large pulmonary vessel ( ) tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>lapatinib</keyword>
	<keyword>TAXOL</keyword>
	<keyword>TYKERB</keyword>
	<keyword>PARAPLATIN</keyword>
</DOC>